Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Structure Therapeutics, Inc. Sponsored ADR (GPCR) vs. Competitors

1,313 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
GPCRStructure Therapeutics, Inc. Sponsored ADR$18.57$1.33B-4.85-49.57%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumGPCRUnlock the GPCR top-analyst price target with TipRanks Premium
LXRXLexicon Pharmaceuticals$1.75$779.16M-12.0117.45%Strong BuyUnlock the LXRX analyst price target with TipRanks PremiumGPCR vs LXRXUnlock the LXRX top-analyst price target with TipRanks Premium
VKTXViking Therapeutics$26.80$3.42B-4.95-31.48%Strong BuyUnlock the VKTX analyst price target with TipRanks PremiumGPCR vs VKTXUnlock the VKTX top-analyst price target with TipRanks Premium
MBXMBX Biosciences, Inc.$53.12$2.64B-17.49114.28%Strong BuyUnlock the MBX analyst price target with TipRanks PremiumGPCR vs MBXUnlock the MBX top-analyst price target with TipRanks Premium
SEPNSepterna, Inc.$41.67$1.98B-31.8879.11%Strong BuyUnlock the SEPN analyst price target with TipRanks PremiumGPCR vs SEPNUnlock the SEPN top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$12.57$1.63B-4.18-51.65%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumGPCR vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
GPCRStructure Therapeutics, Inc. Sponsored ADR18.57-15.93-46.17%
LXRXLexicon Pharmaceuticals1.750.2819.05%
VKTXViking Therapeutics26.80-10.96-29.03%
MBXMBX Biosciences, Inc.53.1226.76101.52%
SEPNSepterna, Inc.41.6719.9892.12%
KLRAKailera Therapeutics, Inc.12.57-13.43-51.65%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts